Cytopenia following axicabtagene ciloleucel (axi-cel) for refractory large B-cell lymphoma (LBCL).

被引：4
|
作者：
Logue, Jennifer Marilyn
Krivenko, Gabriel S.
Larson, Victoria
Bachmeier, Christina A.
Chavez, Julio C.
Davila, Marco L.
Khimani, Farhad
Lazaryan, Aleksandr
Liu, Hien D.
Pinilla-Ibarz, Javier
Shah, Bijal D.
Dholaria, Bhagirathbhai R.
Jain, Michael D.
Locke, Frederick Lundry
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Univ S Florida, Tampa, FL USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[4] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA
[5] West Virginia Univ, Morgantown, WV USA
[6] Vanderbilt Univ, Med Ctr, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e14019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14019
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel).
    Strati, Paolo
    Furqan, Fateeha
    Westin, Jason
    Fayad, Luis
    Ahmed, Sairah
    Lee, Hun Ju
    Iyer, Swaminathan Padmanabhan
    Nair, Ranjit
    Nastoupil, Loretta J.
    Parmar, Simrit
    Rodriguez, Maria Alma
    Samaniego, Felipe
    Steiner, Raphael
    Wang, Michael
    Pinnix, Chelsea Camille
    Flowers, Christopher
    Horowitz, Sandra B.
    Classen, Catherine
    Mistry, Haleigh
    Neelapu, Sattva Swarup
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] PRELIMINARY RESULTS OF THE EARLY USE OF CORTICOSTEROIDS WITH AXICABTAGEN CILOLEUCEL (AXI-CEL) IN PATIENTS DIAGNOSED WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (R/R LBCL)
    Max, Topp S.
    Van Meerten, T.
    Wermke, M.
    Pieternella, Lugtenburg J.
    Monique, Minnema C.
    Kevin, Song W.
    Thieblemont, C.
    Jiang, Y.
    Plaks, V
    Kerber, A.
    Kersten, M. J.
    HAEMATOLOGICA, 2019, 104 : 98 - 98
  • [43] Curative Potential of Axicabtagene Ciloleucel (Axi-Cel): An Exploratory Long-Term Survival Assessment in Patients with Refractory Large B-Cell Lymphoma from ZUMA-1
    Neelapu, Sattva S.
    Jacobson, Caron A.
    Ghobadi, Armin
    Miklos, David B.
    Lekakis, Lazaros J.
    Spooner, Clare
    Kim, Jenny J.
    Miao, Harry
    Xue, Allen Xiaodong
    Zheng, Yan
    Locke, Frederick L.
    BLOOD, 2023, 142
  • [44] ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL)
    Kenderian, Saad S.
    Oluwole, Olalekan O.
    McCarthy, Philip L.
    Reshef, Ran
    Shiraz, Parveen
    Ahmed, Omar
    Le Gall, John
    Nahas, Myrna
    Tang, Lily
    Neelapu, Sattva S.
    BLOOD, 2020, 136
  • [45] Matching-Adjusted Indirect Comparison (MAIC) of Axicabtagene Ciloleucel (Axi-Cel) and Lisocabtagene Maraleucel (Liso-Cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) After Two or More Prior Lines of Therapy
    Oluwole, Olalekan O.
    Chen, Jenny M. H.
    Chan, Keith
    Patel, Anik R.
    Jansen, Jeroen P.
    Keeping, Sam
    Bashir, Zahid
    Zheng, Yan
    Snider, Julia
    Locke, Frederick L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S388 - S388
  • [46] Cytokines associated with prolonged Cytopenia after axicabtagene ciloleucel in patients with refractory large B-cell lymphoma
    Strati, Paolo
    Puebla-Osorio, Nahum
    Han, Guangchun
    Westin, Jason
    Nastoupil, Loretta
    Samaniego, Felipe
    Fowler, Nathan
    Fayad, Luis
    Lee, Hun Ju
    Flowers, Christopher
    Srour, Samer
    Watson, Grace
    Wang, Linghua
    Green, Michael
    Neelapu, Sattva
    CANCER RESEARCH, 2020, 80 (16)
  • [47] Axicabtagene Ciloleucel (Axi-cel) in Patients With Refractory Large B Cell Lymphoma (NHL): Long-term Follow-up of ZUMA-1
    Locke, F. L.
    Bartlett, N. L.
    Lekakis, L. J.
    Miklos, D. B.
    Jacobson, C. A.
    Braunschweig, I.
    Oluwole, O. O.
    Siddiqi, T.
    Lin, Y.
    Timmerman, J.
    Reagan, P. M.
    Bot, A.
    Rossi, J. M.
    Navale, L.
    Jiang, Y.
    Aycock, J. S.
    Elias, M.
    Wiezorek, J. S.
    Go, W.
    Neelapu, S. S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 25 - 25
  • [48] ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) plus Utomilumab Patients with Refractory Large B Cell Lymphoma
    Reshef, Ran
    Miklos, David B.
    Timmerman, John M.
    Jacobson, Caron A.
    Bennani, Nabila N.
    Rossi, John M.
    Sherman, Marika
    Zheng, Lianqing
    Sun, Jennifer
    Palluconi, Gabrielle
    Kim, Jenny J.
    Jain, Michael D.
    BLOOD, 2019, 134
  • [49] ZUMA-12: A phase 2 multicenter study of axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients (pts) with high-risk large B-cell lymphoma (LBCL).
    Neelapu, Sattva Swarup
    Chavez, Julio C.
    Lin, Yi
    Munoz, Javier
    Ujjani, Chaitra Shankar
    Riedell, Peter
    De Vos, Sven
    Oluwole, Olalekan O.
    Kekre, Natasha
    Yang, Yin
    Goyal, Lovely
    Backhouse, Kate
    Milletti, Francesca
    Kawashima, Jun
    Herrera, Alex Francisco
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] Single-Center Experience with Axicabtagene-Ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Comparable Response Rates and Manageable Toxicity
    Buecklein, Veit
    Blumenberg, Viktoria
    Ackermann, Josephine
    Schmidt, Christian
    Rejeski, Kai
    Mueller, Niklas
    Reischer, Anna
    von Baumgarten, Louisa
    Schoeberl, Florian
    Humpe, Andreas
    von Bergwelt, Michael
    Subklewe, Marion
    BLOOD, 2020, 136
12345